How are Sanofi tackling the challenges of Alliance Management?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How are Sanofi tackling the challenges of Alliance Management?
Released on: September 12, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Studies show that the number of corporate alliances increases by some 25% a year—yet the failure rate for alliances hovers between 60% and 70%.
  • Summary
  • Transcript
  • Participants
  • Company
Studies show that the number of corporate alliances increases by some 25% a year—yet the failure rate for alliances hovers between 60% and 70%. During the WPLC in London, Frank Grams, Vice President, Head Alliance Management & Transactions, Sanofi, explains to Fiona Gardner the steps they have taken to address the challenges in this area including the launch of their Alliance Academy and the introduction of regular alliance health checks.
Studies show that the number of corporate alliances increases by some 25% a year—yet the failure rate for alliances hovers between 60% and 70%. During the WPLC in London, Frank Grams, Vice President, Head Alliance Management & Transactions,explains to Fiona Gardner the steps they have taken to address the challenges in this area including the launch of their Alliance Academy and the introduction of regular alliance health checks.
Frank Grams
Sanofi
sanofi
Sanofi, headquartered in Paris, France, is a multinational pharmaceutical company, the world's fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary sanofi pasteur).